Microfluidic-based patient-derived organoids recapitulate thyroid cancer heterogeneity and reveal NF-κB-driven maturation for precision therapy
Open Access
- 27 February 2026
- journal article
- research article
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 24 (1)
Abstract
Inter-tumor heterogeneity poses significant challenges for precision therapy in thyroid cancer (TC). The conventional organoid models are limited by ineffiKeywords
Funding Information
- Science and Technology Projects in Guangzhou (2025A03J3474)
- Fundamental Research Funds for the Central Universities (21625311)
- the Shenzhen Fundamental Research Program (JCYJ20240813112004006)
This publication has 47 references indexed in Scilit:
- Rationale of using immune checkpoint inhibitors (ICIs) and anti-angiogenic agents in cancer treatment from a molecular perspectiveClinical and Experimental Medicine, 2025
- Impact of Genetic Polymorphisms on Treatment Outcomes of Proteasome Inhibitors and Immunomodulatory Drugs in Multiple MyelomaCurrent Treatment Options in Oncology, 2025
- Meta-Analytical and Meta-Regression Evaluation of Subclinical Hyperthyroidism's Effect on Male Reproductive Health: Hormonal and Seminal PerspectivesReproductive Sciences, 2024
- Thyroid CancerJAMA, 2024
- Advances in Microfluidic Technologies in Organoid ResearchAdvanced Healthcare Materials, 2023
- Organs-on-chips technologies – A guide from disease models to opportunities for drug developmentBiosensors and Bioelectronics, 2023
- Calcitonin testing for detection of medullary thyroid cancer in people with thyroid nodulesCochrane Database of Systematic Reviews, 2020
- Organoid Modeling of the Tumor Immune MicroenvironmentCell, 2018
- Clinical and prognostic role of detection timing of distant metastases in patients with differentiated thyroid cancerEndocrine, 2018
- Clinicopathological Characteristics and Long‐term Outcome in Patients with Distant Metastases from Differentiated Thyroid CancerWorld Journal of Surgery, 2006